Literature DB >> 389479

Potential of liposomes as drug-carriers in cancer chemotherapy: a review.

S B Kaye, V J Richardson.   

Abstract

Liposomes are bilayered phospholipid vesicles that have been proposed as vehicles for the selective delivery of cytotoxic drugs into malignant cells. In vitro and in vivo experiments have indicated that the activity of a range of drugs or their active metabolites may be enhanced by encapsulation in liposomes, particularly when used against drug-resistant tumours. Moreover, liposomal entrapment certainly has a marked effect on the tissue distribution and rates of clearance of cytotoxic drugs, and also appears to reduce their toxicity in most cases. However, in both animal and patient studies, the major sites of uptake following IV administration consistently appear as the liver and spleen. Preferential tumour uptake has therefore not yet been achieved, althrough a degree of localization of liposomal labels can be demonstrated in the vicinity of experimental animal tumours in certain circumstances. Liposomes may have a future role in cancer chemotherapy, but much laboratory work remains to be done before clinical application can be considered.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 389479     DOI: 10.1007/bf00254977

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  46 in total

1.  Studies on the metabolism of radioactive albumin in tumor-bearing rats.

Authors:  H BUSCH; E FUJIWARA; D C FIRSZT
Journal:  Cancer Res       Date:  1961-04       Impact factor: 12.701

2.  Application of liposomes to the pharmaceutical modification of the distribution characteristics of drugs in the rat.

Authors:  T Tanaka; K Taneda; H Kobayashi; K Okumura; S Muranishi; H Sezaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1975-12       Impact factor: 1.645

3.  Liposomal potentiation of the antitumor activity of alkylating drugs.

Authors:  R J Rutman; C A Ritter; N G Avadhani; J Hansel
Journal:  Cancer Treat Rep       Date:  1976-05

4.  The carrier potential of liposomes in biology and medicine (first of two parts).

Authors:  G Gregoriadis
Journal:  N Engl J Med       Date:  1976-09-23       Impact factor: 91.245

5.  Drug-containing lipid vesicles render drug-resistant cell sensitive to actinomycin D.

Authors:  G Poste; D Papahadjopoulos
Journal:  Nature       Date:  1976-06-24       Impact factor: 49.962

Review 6.  Perspectives in cancer research. Increased selectivity of drugs by linking to carriers.

Authors:  A Trouet
Journal:  Eur J Cancer       Date:  1978-02       Impact factor: 9.162

7.  Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin.

Authors:  H Riehm; J L Biedler
Journal:  Cancer Res       Date:  1972-06       Impact factor: 12.701

8.  Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin.

Authors:  R L Juliano; D Stamp
Journal:  Biochem Pharmacol       Date:  1978-01-01       Impact factor: 5.858

9.  Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation.

Authors:  Y E Rahman; W R Hanson; J Bharucha; E J Ainsworth; B N Jaroslow
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

10.  Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles.

Authors:  E Mayhew; D Papahadjopoulos; Y M Rustum; C Dave
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

View more
  7 in total

Review 1.  Immunoglobulins as targeting agents for liposome encapsulated drugs.

Authors:  P A Toonen; D J Crommelin
Journal:  Pharm Weekbl Sci       Date:  1983-12-16

2.  Nanoliposomal formulation of pistachio hull extract: preparation, characterization and anti-cancer evaluation through Bax/Bcl2 modulation.

Authors:  Hamidreza Harandi; Soudeh Khanamani Falahati-Pour; Mehdi Mahmoodi; Sanaz Faramarz; Haniyeh Maleki; Fatemeh Bagheri Nasab; Hamidreza Shiri; Saba Fooladi; Mohammad Hadi Nematollahi
Journal:  Mol Biol Rep       Date:  2022-01-17       Impact factor: 2.316

3.  Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).

Authors:  R Perez-Soler; J Lautersztain; L C Stephens; K Wright; A R Khokhar
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  pH-triggered echogenicity and contents release from liposomes.

Authors:  Rahul Nahire; Rayat Hossain; Rupa Patel; Shirshendu Paul; Varsha Meghnani; Avinash H Ambre; Kara N Gange; Kalpana S Katti; Estelle Leclerc; D K Srivastava; Kausik Sarkar; Sanku Mallik
Journal:  Mol Pharm       Date:  2014-10-16       Impact factor: 4.939

5.  Pegylated liposomal doxorubicin in ovarian cancer.

Authors:  Robert Strother; Daniela Matei
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

6.  Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro.

Authors:  V J Richardson; G A Curt; B E Ryman
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

7.  Targeting doxorubicin encapsulated in stealth liposomes to solid tumors by non thermal diode laser.

Authors:  Magdy M Ghannam; Reem El Gebaly; Maha Fadel
Journal:  Lipids Health Dis       Date:  2016-04-05       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.